title: BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
abstract: Venetoclax is an oral drug with an excellent side-effect profile that has the potential to revolutionize acute myeloid leukemia (AML) therapy in two areas. Venetoclax-based combination therapies could be a bridge to hematopoietic cell transplant with curative intent for patients with refractory/relapsed AML, and venetoclax-based therapy could provide meaningful survival prolongation for older patients with AML who are not candidates for more aggressive therapies. Cancer Discov; 6(10); 1082-3. ©2016 AACR.See related article by Konopleva and colleagues, p. 1106.
authors.affiliation: Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California. vpullarkat@coh.org.
authors.forename: Vinod A
authors.initials: VA
authors.lastname: Pullarkat
authors.affiliation: Department Cancer Biology, Beckman Research Institute of City of Hope, Duarte, California.
authors.forename: Edward M
authors.initials: EM
authors.lastname: Newman
mesh_terms: D019086:Bridged Bicyclo Compounds, Heterocyclic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D013449:Sulfonamides
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D013449:Sulfonamides; C579720:venetoclax